Search

Your search keyword '"Tourbah, Ayman"' showing total 354 results
Start Over Author "Tourbah, Ayman"
354 results on '"Tourbah, Ayman"'

4. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Author

Agüera Morales, Eduardo, Al Khedr, Abdullatif, Ampapa, Radek, Arroyo, Rafael, Belkin, Martin, Bonek, Robert, Boyko, Alexey, Capra, Ruggero, Centonze, Diego, Clavelou, Pierre, Debouverie, Marc, Drulovic, Jelena, Edwards, Keith, Evangelou, Nikos, Evdoshenko, Evgeniy, Fernández, Oscar, Fernández Sánchez, Victoria, Freedman, Mark, Freedman, Steven, Fryze, Waldemar, Garcia-Merino, Antonio, Gavric-Kezic, Mira, Ghezzi, Angel, Gout, Olivier, Grimaldi, Luigi, Hendin, Barry, Hertmanowska, Hanka, Hintzen, Rogier, Hradilek, Pavel, Hupperts, Raymond, Ilkowski, Jan, Ivashinenkova, Evelina, Izquierdo, Guillermo, Jacques, Francois, Jakab, Gabor, Khabirov, Farit, Klodowska-Duda, Gabriela, Komoly, Samuel, Kostic, Smiljana, Kovarova, Ivana, Kremenchuzky, Marcelo, Laganke, Christopher, LaPierre, Yves, Maciejowski, Maciej, Maison, Francois Grand, Marfia, Girolama Alessandra, Martínez Yélamos, Sergio, Meluzinova, Eva, Montalban, Xavier, Murray, Ronald, Naismith, Robert, Newsome, Scott, Nguyen, Viet, Oreja, Delia, Pardo, Gabriel, Pasechnik, Elena, Patti, Francesco, Potemkowski, Andrzej, Prokopenko, Semen, Qian, Peiqing, Rodríguez-Antigüedad, Alfredo, Rossman, Howard, Rozsa, Csilla, Sánchez López, Fernando, Selmaj, Krzysztof, Silber, Eli, Stepien, Adam, Stepniewska, Anna, Swiat, Maciej, Toncev, Gordana, Tourbah, Ayman, Trushnikova, Tatyana, Uccelli, Antonio, Vachova, Marta, Valis, Martin, Vecsei, Laszlo, Wiertlewski, Sandrine, Zaffaroni, Mauro, Zielinski, Tomasz, Cadavid, Diego, Mellion, Michelle, Edwards, Keith R, Calabresi, Peter A, Drulović, Jelena, Giovannoni, Gavin, Hartung, Hans-Peter, Arnold, Douglas L, Fisher, Elizabeth, Rudick, Richard, Mi, Sha, Chai, Yi, Li, Jie, Zhang, Yiwei, Cheng, Wenting, Xu, Lei, Zhu, Bing, Green, Susan M, Chang, Ih, Deykin, Aaron, and Sheikh, Sarah I

Published
2019
Full Text
View/download PDF

7. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

Author

Laplaud, David-Axel, Casey, Romain, Barbin, Laetitia, Debouverie, Marc, De Sèze, Jérôme, Brassat, David, Wiertlewski, Sandrine, Brochet, Bruno, Pelletier, Jean, Vermersch, Patrick, Edan, Gilles, Lebrun-Frenay, Christine, Clavelou, Pierre, Thouvenot, Eric, Camdessanché, Jean-Philippe, Tourbah, Ayman, Stankoff, Bruno, Al Khedr, Abdullatif, Cabre, Philippe, Lubetzki, Catherine, Papeix, Caroline, Berger, Eric, Heinzlef, Olivier, Debroucker, Thomas, Moreau, Thibault, Gout, Olivier, Bourre, Bertrand, Wahab, Abir, Labauge, Pierre, Magy, Laurent, Defer, Gilles, Guennoc, Anne-Marie, Maubeuge, Nicolas, Labeyrie, Céline, Patry, Ivania, Nifle, Chantal, Casez, Olivier, Michel, Laure, Rollot, Fabien, Leray, Emmanuelle, Vukusic, Sandra, Foucher, Yohann, Fontaine, B., Marignier, R., Durand-Dubief, F., Mathey, G., Le Page, E., Peaureaux-Averseng, D., Ouallet, J.C., Ruet, A., Collongues, N., Hautecoeur, P., Zephir, H., Maillard, E., Cohen, M., Derache, N., Branger, P., Ayrignac, X., Carra-Dalliere, C., Fromont, A., Chamard-Witkowski, L., Taithe, F., Moisset, X., Audoin, B., Rico-Lamy, A., Castelnovo, G., Giannesini, C., Fagniez, O., Bensa, C., Gueguen, A., Kasonde, I. Tabellah, De Vilmarest, A., Montcuquet, A., Vaillants, M., Beltran, S., Creange, A., Ayache, S., Abdellaoui, M., Pottier, C., Slesari, I., Deburghraeve, V., Neau, J.P., Servan, J., Pico, F., Henry, C., and Hankiewicz, K.

Published
2019
Full Text
View/download PDF

9. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study

Author

Papeix, Caroline, Castelnovo, Giovanni, Leray, Emmanuelle, Coustans, Marc, Levy, Pierre, Visy, Jean-Marc, Kobelt, Gisela, Lamy, Fabienne, Allaf, Bashar, Heintzmann, François, Chouette, Isabelle, Raponi, Eric, Durand, Barbara, Grevat, Emmanuelle, Kamar, Driss, Debouverie, Marc, Lebrun-Frenay, Christine, Abdelmoumni, Abdelhakim, Al Aloucy, Mouhmmad Jamal, Al Khedr, Abdullatif, Al Najjar Carpentier, Amer, Alonzo, Bernard, Altarcha, Tony, Ananivi, Amevi, Androdias, Géraldine, Angibaud, Gilles, Artaud-Uriot, Marie-Sylvie, Audry-Chaboud, Dominique, Barre, Marie, Barres, Philippe, Benrabah, Rabah, Berger, Eric, Bergouignan, François-Xavier, Bernady, Patricia, Billy, Christophe, Blanchard, Christian, Bonnan, Mickaël, Borsotti, Jean-Paul, Bossu-van Nieuwenhuyse, Catherine, Bouffeteau, Jean-Claude, Bouillaguet, Sophie, Boukriche, Yassine, Boulesteix, Jean-Marc, Bourre, Bertrand, Brassat, David, Bredin, Alain, Brochet, Bruno, Brugeilles Baguelin, Helene, Camara, Ousmane, Camdessanche, Jean-Philippe, Camu, William, Carel, Christophe, Carlander, Bertrand, Casez, Olivier, Chanel-Soulier, Marie-Pierre, Chapuis, Stéphane, Cimpoesu, Mirella, Ciron, Jonathan, Clavelou, Pierre, Clerc, Christine, Colamarino, Renato, Couratier, Christophe, Courtois, Sylvie, Creange, Alain, Danielli, Antoine, de Broucker, Thomas, de Seze, Jérôme, Defer, Gilles, Delorme, Jérôme, Denis, Béatrice, Derouiche, Fayçal, Devos, Philippe, Deyrolle, Anne-Marie, Dib, Michel, Dib, Joseph, Diot, Eric, Doury, Emmanuelle, Dufourd-Delalande, Sophie, Dupel-Pottier, Corinne, Dussaux, Patrick, Edan, Gilles, Edouard, Thibault, Escaillas, Jean-Pierre, Ferriby, Didier, Fouillet, Nicolas, Fromager, Guillaume, Gaida-Rostane, Tsouria, Gaida, Philippe, Gal, Guillaume, Garrigues, Guillaume, Gayou-Joyeux, Annick, Gentil, Arnaud, Gerard, Philippe, Gere, Julien, Gignoux, Laurence, Girard, Philippe, Giraud, Pierric, Gouttard, Michel, Gras, Pierre, Guennoc, Anne Marie, Gugenheim, Michel, Guilloton, Laurent, Hadjout, Karim, Hautecoeur, Patrick, Hegbe, Yawo, Heinzlef, Olivier, Henry, Patrice, Herve, Yann, Hijazi, Jihad, Homeyer, Pascale, Huttin, Bernard, Ille, Olivier, Jager, Alain, Jomir, Laurentiu, Kardous, Nabil, Kerouanton, Agnès, Kpade, Comlan Paul, Kubler, Christophe, Labauge, Pierre, Lallement, François, Landragin, Nicolas, Laplaud, David Axel, Laribi, Henda, Lavernhe, Gilles, Le Biez, Pierre-Éric, Le Bras, Françoise, Le Coz, Patrick, Leche, Josette, Leder, Sara Julia, Legout, Alain, Levasseur, Michele, Lorenzi-Pernot, Alberta, Louchart, Pierre, Louillet, Fabien, Magy, Laurent, Maillard, Sophie, Maillart, Elisabeth, Maillet-Vioud, Marcel, Mallecourt-Emberger, Catherine, Manchon, Éric, Mania, Alexandre, Martinez-Almoyna, Laurent, Martinez, Mikel, Massengo, Serge, Maugin, Dominique, Medjbeur, Souraya, Meliksetyan, Gayané, Menassa, Michael, Meshaka-Dimitri-Boulos, Dalia, Mick, Gérard, Moreau, Thibault, Moulignier, Antoine, Mourand, Isabelle, Muller, Jean-Philippe, Neuschwander, Philippe, Nibbio, Argentino, Nifle, Chantal, Nkendjuo, Jean-Bertin, Nokam Talom, Ghislain, Ory, Sophie, Patry, Ivania, Pedespan, Bernard, Pelletier, Jean, Pencu, Delia-Gianina, Perrouty, Bruno, Peysson, Stéphane, Popa-Coman, Irène, Pouliquen, André, Prat, Christophe, Prundean, Adriana, Radji, Fataï, Rakotoharinandrasana, Haja Tiana, Razlog, Lilia, Remy, Philippe, Robin, Christophe, Rodier, Gilles, Romero, Jérôme, Roualdes, Brigitte, Rouhart, François, Ruggieri, Irene, Samad, Feras Abdul, Sarafiant, Irina, Schaeffer, Stephane, Schmidt, Nicolas, Schuermans, Philippe, Seiller, Nicolas, Soisson, Thierry, Sortais, Annie, Stankoff, Bruno, Stefanizzi-Debuc, Sabrina, Suchet, Laurent, Tardy, Jean, Taurin, Gregory, Thabuy, Florent, Theaudin, Marie, Tilikete-Froment, Caroline, Tourbah, Ayman, Tourniaire, Patricia, Trefouret, Sylvie, Vastene, Michel, Verdure, Pierre, Vermersch, Patrick, Viala, Frédérique, Videt-Gibou, Dorothée, Vidry, Elisabeth, Vukusic, Sandra, Wagner, Marc, Wattier, Valery, Zaenker, Christophe, Ziegler, François, Zola, Jean-Médard, Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), and Collectif de recherche handicap, autonomie et société inclusive (CoRHASI)

Subjects
Quality of life, Disability, Neurology, Relapsing–remitting multiple sclerosis, Radiological markers, Disease-modifying treatment, Effectiveness, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), Tolerability
Abstract

Online ahead of print; International audience; Introduction: It is important to confirm the effectiveness and tolerability of disease-modifying treatments for relapsing-remitting multiple sclerosis (RRMS) in real-world treatment settings. This prospective observational cohort study (VIRGILE) was performed at the request of the French health authorities. The primary objective was to evaluate the effectiveness of fingolimod 0.5 mg in reducing the annualised relapse rate (ARR) in patients with RRMS.Methods: Participating neurologists enrolled all adult patients with RRMS starting fingolimod treatment between 2014 and 2016, who were followed for 3 years. Follow-up consultations took place at the investigator's discretion. The primary outcome measure was the change in ARR at month 24 after fingolimod initiation. Relapses and adverse events were documented at each consultation; disability assessment (EDSS) and magnetic resonance imagery were performed at the investigator's discretion.Results: Of 1055 eligible patients, 633 patients were assessable at month 36; 405 (64.0%) were treated continuously with fingolimod for 3 years. The ARR decreased from 0.92 ± 0.92 at inclusion to 0.31 ± 0.51 at month 24, a significant reduction of 0.58 [95% CI - 0.51 to - 0.65] relapses/year (p < 0.001). Since starting fingolimod, 461 patients (60.9%) remained relapse-free at month 24 and 366 patients (55.5%) at month 36. In multivariate analysis, no previous disease-modifying treatment, number of relapses in the previous year and lower EDSS score at inclusion were associated with a greater on-treatment reduction in ARR. The mean EDSS score remained stable over the course of the study. Sixty-one out of 289 (21.1%) patients presented new radiological signs of disease activity. Treatment-related serious adverse events were lymphopenia (N = 21), bradycardia (N = 19), elevated transaminases (N = 9) and macular oedema (N = 9).Conclusions: The effectiveness and tolerability of fingolimod in everyday clinical practice are consistent with findings of previous phase III studies. Our study highlights the utility of fingolimod for the long-term management of patients with multiple sclerosis.

Published
2022

12. Prospective Characterization of Brain T2 Lesions Suggestive of Demyelination in Asymptomatic Patients diagnosed as Radiologically Isolated Syndrome (P14-4.011)

Author

Landes-Château, Cassandre, primary, Mondot, Lydiane, additional, Cohen, Mikael, additional, Callier, Céline, additional, Zephir, Helene, additional, Louapre, Celine, additional, Dubief, Francoise Durand, additional, Carra-Dalliere, Clarisse, additional, Thouvenot, Eric, additional, Le Page, Emmanuelle, additional, Ruet, Aurelie, additional, Berger, Eric, additional, Derache, Nathalie, additional, Clavelou, Pierre, additional, Moreau, Thibault, additional, Casez, Olivier, additional, Gout, Olivier, additional, De Seze, Jerome, additional, Ciron, Jonathan, additional, Wiertlewski, Sandrine, additional, Bourre, Bertrand, additional, Magy, Laurent, additional, Cabre, Philippe, additional, Pelletier, Jean, additional, Debouverie, Marc, additional, Stankoff, Bruno, additional, Creange, Alain, additional, Fagniez, Ombeline, additional, Pottier, Corinne, additional, Neau, Jean Philippe, additional, Camdessanche, Jean-Philippe, additional, Henry, Carole, additional, Beltran, Stephane, additional, Guennoc, Anne Marie, additional, Tourbah, Ayman, additional, Radji, Fatai, additional, Morel, Nathalie, additional, Boyer, Karine, additional, Al Khedr, Abdullatif, additional, Siva, Aksel, additional, Kantarci, Orhun, additional, Pelletier, Daniel, additional, Okuda, Darin, additional, and Lebrun-Frenay, Christine, additional

Published
2022
Full Text
View/download PDF

13. MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis

Author

Tanoh, Ian-Christopher, primary, Maillart, Elisabeth, additional, Labauge, Pierre, additional, Cohen, Mikael, additional, Maarouf, Adil, additional, Vukusic, Sandra, additional, Donzé, Cécile, additional, Gallien, Philippe, additional, De Sèze, Jérôme, additional, Bourre, Bertrand, additional, Moreau, Thibault, additional, Louapre, Céline, additional, Vallée, Morgane, additional, Bieuvelet, Séverine, additional, Klaeylé, Lissandra, additional, Argoud, Anne-Laure, additional, Zinaï, Saad, additional, and Tourbah, Ayman, additional

Published
2021
Full Text
View/download PDF

15. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab

Author

Fissolo, Nicolás, Pignolet, Beatrice, Rio, Jordi, Vermersch, Patrick, Ruet, Aurélie, deSèze, Jerome, Labauge, Pierre, Vukusic, Sandra, Papeix, Caroline, Martinez-Almoyna, Laurent, Tourbah, Ayman, Clavelou, Pierre, Moreau, Thibault, Pelletier, Jean, Lebrun-Frenay, Christine, Bourre, Bertrand, Defer, Gilles, Montalban, Xavier, Brassat, David, Comabella, Manuel, Universitat Autònoma de Barcelona, Fissolo, Nicolás, Pignolet, Beatrice, Rio, Jordi, Vermersch, Patrick, Ruet, Aurélie, deSèze, Jerome, Labauge, Pierre, Vukusic, Sandra, Papeix, Caroline, Martinez-Almoyna, Laurent, Tourbah, Ayman, Clavelou, Pierre, Moreau, Thibault, Pelletier, Jean, Lebrun-Frenay, Christine, Bourre, Bertrand, Defer, Gilles, Montalban, Xavier, Brassat, David, Comabella, Manuel, and Universitat Autònoma de Barcelona

Abstract

The study aimed to assess the potential for serum neurofilament light chain (NFL) levels to predict the risk of progressive multifocal leukoencephalopathy (PML) in natalizumab (NTZ)-treated patients with multiple sclerosis (MS) and to discriminate PML from MS relapses. NFL levels were measured with single molecule array (Simoa) in 4 cohorts: (1) a prospective cohort of patients with MS who developed PML under NTZ therapy (pre-PML) and non-PML NTZ-treated patients (NTZ-ctr); (2) a cohort of patients whose blood was collected during PML; (3) an independent cohort of non-PML NTZ-treated patients with serum NFL determinations at 2 years (replication cohort); and (4) a cohort of patients whose blood was collected during exacerbations. Serum NFL levels were significantly increased after 2 years of NTZ treatment in pre-PML patients compared with NTZ-ctr. The prognostic performance of serum NFL levels to predict PML development at 2 years was similar in the NTZ-ctr group and replication cohort. Serum NFL levels also distinguished PML from MS relapses and were 8-fold higher during PML compared with relapses. These results support the use of serum NFL levels in clinical practice to identify patients with relapsing-remitting MS at higher PML risk and to differentiate PML from clinical relapses in NTZ-treated patients. This study provides Class I evidence that serum NFL levels can identify NTZ-treated patients with MS who will develop PML with a sensitivity of 67% and specificity of 80%

Published
2021

19. Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study

Author

Cohen, Mikael, Maillart, Elisabeth, Tourbah, Ayman, De Sèze, Jérôme, Vukusic, Sandra, Brassat, David, Anne, Olivier, Wiertlewski, Sandrine, Camu, William, Courtois, Sylvie, Ruet, Aurélie, Debouverie, Marc, Le Page, Emmanuelle, Casez, Olivier, Heinzlef, Olivier, Stankoff, Bruno, Bourre, Bertrand, Castelnovo, Giovanni, Rico, Audrey, Berger, Eric, Camdessanche, Jean-Philippe, Defer, Gilles, Clavelou, Pierre, Al Khedr, Abdullatif, Zephir, Hélène, Fromont, Agnès, Papeix, Caroline, Brochet, Bruno, Pelletier, Jean, and Lebrun, Christine

Published
2014
Full Text
View/download PDF

22. Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease

Author

Ameli, Roxana, primary, Guttmann, Charles R.G., additional, Prieto, Juan Carlos, additional, Rollot, Fabien, additional, Palotai, Miklos, additional, Vukusic, Sandra, additional, Marignier, Romain, additional, Cotton, François, additional, Anxionnat, René, additional, Armspach, Jean-Paul, additional, Audoin, Bertrand, additional, Barillot, Christian, additional, Berry, Isabelle, additional, Bonneville, Fabrice, additional, Boutet, Claire, additional, Castelnovo, Giovanni, additional, Cervenanski, Frédéric, additional, Cohen, Mikael, additional, Commowick, Olivier, additional, De Seze, Jerome, additional, Dousset, Vincent, additional, Durand-Dubief, Francoise, additional, Edan, Gilles, additional, Ferre, Jean-Christophe, additional, Galanaud, Damien, additional, Glattard, Tristan, additional, Grand, Sylvie, additional, Guillaumont, Justine, additional, Guillevin, Rémy, additional, Hannoun, Salem, additional, Heitz, Fabrice, additional, Krainik, Alexandre, additional, Kremer, Stéphane, additional, Labauge, Pierre, additional, Menjot De Champfleur, Nicolas, additional, Ranjeva, Jean-Philippe, additional, Roch, Jean-Amédée, additional, Sappey-Marinier, Dominique, additional, Savatovsky, Julien, additional, Stankoff, Bruno, additional, Tourbah, Ayman, additional, Tourdias, Thomas, additional, Brochet, Bruno, additional, Clanet, Michel, additional, Dufay, Nathalie, additional, Laplaud, David, additional, Maze, Marie-Claire, additional, Moreau, Thibault, additional, Trolliet, Cédric, additional, Frangoulis, Bernard, additional, Olaiz, Javier, additional, Pelletier, Jean, additional, Bourre, Bertrand, additional, Brassat, David, additional, Cabre, Philippe, additional, Camdessanche, Jean-Philippe, additional, Camu, William, additional, Casez, Olivier, additional, Clavelou, Pierre, additional, Collongues, Nicolas, additional, Creange, Alain, additional, Defer, Gilles, additional, Debouverie, Marc, additional, Gout, Olivier, additional, Lebrun-Frenay, Christine, additional, Lubetzki, Catherine, additional, Papeix, Caroline, additional, Vermersch, Patrick, additional, and Zephir, Hélène, additional

Published
2021
Full Text
View/download PDF

23. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab

Author

Fissolo, Nicolás, primary, Pignolet, Beatrice, additional, Rio, Jordi, additional, Vermersch, Patrick, additional, Ruet, Aurélie, additional, deSèze, Jerome, additional, Labauge, Pierre, additional, Vukusic, Sandra, additional, Papeix, Caroline, additional, Martinez-Almoyna, Laurent, additional, Tourbah, Ayman, additional, Clavelou, Pierre, additional, Moreau, Thibault, additional, Pelletier, Jean, additional, Lebrun-Frenay, Christine, additional, Bourre, Bertrand, additional, Defer, Gilles, additional, Montalban, Xavier, additional, Brassat, David, additional, and Comabella, Manuel, additional

Published
2021
Full Text
View/download PDF

25. Social cognition and executive functioning in multiple sclerosis: A cluster‐analytic approach.

Author

Henry, Audrey, Lannoy, Séverine, Chaunu, Marie‐Pierre, Tourbah, Ayman, and Montreuil, Michèle

Subjects
SOCIAL perception, EXECUTIVE function, MULTIPLE sclerosis, EMOTION recognition, SOCIAL interaction, FACIAL expression & emotions (Psychology), DISEASE duration
Abstract

Multiple sclerosis (MS) is associated with deficits in social cognition, the process underlying social interaction and cognitive function. However, the relationships between executive impairment and social cognition remain unclear in MS. Previous studies exclusively focused on group comparisons between healthy controls and patients with MS, treating the latter as a homogeneous population. The variability of socio‐ and neurocognitive profiles in this pathology therefore remains underexplored. In the present study, we used a cluster analytic approach to explore the heterogeneity of executive and social cognition skills in MS. A total of 106 patients with MS were compared with 53 healthy matched controls on executive (e.g., working memory) and social cognition (facial emotion recognition and theory of mind) performances. A cluster analysis was then performed, focusing on the MS sample, to explore the presence of differential patterns of interaction between executive and social cognition difficulties and their links to sociodemographic, clinical and cognitive variables. We identified three distinct functional profiles: patients with no executive or social cognition deficits (Cluster 1); patients with difficulties in facial emotion recognition and theory of mind and, to a lesser extent, executive functioning (Cluster 2); and patients with executive functioning difficulties only (Cluster 3). Clinical characteristics (disease duration, disability, fatigue) did not differ between clusters. Conclusions: These results suggest that there are qualitative differences in the social cognition and executive difficulties that are commonly found among patients with MS. If replicated, the identification of these profiles in clinical practice could allow for more individualized rehabilitation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Author

Sawcer, Stephen, Hellenthal, Garrett, Pirinen, Matti, Spencer, Chris C. A., Patsopoulos, Nikolaos A., Moutsianas, Loukas, Dilthey, Alexander, Su, Zhan, Freeman, Colin, Hunt, Sarah E., Edkins, Sarah, Gray, Emma, Booth, David R., Potter, Simon C., Goris, An, Band, Gavin, Bang Oturai, Annette, Strange, Amy, Saarela, Janna, Bellenguez, Céline, Fontaine, Bertrand, Gillman, Matthew, Hemmer, Bernhard, Gwilliam, Rhian, Zipp, Frauke, Jayakumar, Alagurevathi, Martin, Roland, Leslie, Stephen, Hawkins, Stanley, Giannoulatou, Eleni, D’alfonso, Sandra, Blackburn, Hannah, Martinelli Boneschi, Filippo, Liddle, Jennifer, Harbo, Hanne F., Perez, Marc L., Spurkland, Anne, Waller, Matthew J., Mycko, Marcin P., Ricketts, Michelle, Comabella, Manuel, Hammond, Naomi, Kockum, Ingrid, McCann, Owen T., Ban, Maria, Whittaker, Pamela, Kemppinen, Anu, Weston, Paul, Hawkins, Clive, Widaa, Sara, Zajicek, John, Dronov, Serge, Robertson, Neil, Bumpstead, Suzannah J., Barcellos, Lisa F., Ravindrarajah, Rathi, Abraham, Roby, Alfredsson, Lars, Ardlie, Kristin, Aubin, Cristin, Baker, Amie, Baker, Katharine, Baranzini, Sergio E., Bergamaschi, Laura, Bergamaschi, Roberto, Bernstein, Allan, Berthele, Achim, Boggild, Mike, Bradfield, Jonathan P., Brassat, David, Broadley, Simon A., Buck, Dorothea, Butzkueven, Helmut, Capra, Ruggero, Carroll, William M., Cavalla, Paola, Celius, Elisabeth G., Cepok, Sabine, Chiavacci, Rosetta, Clerget-Darpoux, Françoise, Clysters, Katleen, Comi, Giancarlo, Cossburn, Mark, Cournu-Rebeix, Isabelle, Cox, Mathew B., Cozen, Wendy, Cree, Bruce A. C., Cross, Anne H., Cusi, Daniele, Daly, Mark J., Davis, Emma, de Bakker, Paul I. W., Debouverie, Marc, D’hooghe, Marie Beatrice, Dixon, Katherine, Dobosi, Rita, Dubois, Bénédicte, Ellinghaus, David, Elovaara, Irina, Esposito, Federica, Fontenille, Claire, Foote, Simon, Franke, Andre, Galimberti, Daniela, Ghezzi, Angelo, Glessner, Joseph, Gomez, Refujia, Gout, Olivier, Graham, Colin, Grant, Struan F. A., Rosa Guerini, Franca, Hakonarson, Hakon, Hall, Per, Hamsten, Anders, Hartung, Hans-Peter, Heard, Rob N., Heath, Simon, Hobart, Jeremy, Hoshi, Muna, Infante-Duarte, Carmen, Ingram, Gillian, Ingram, Wendy, Islam, Talat, Jagodic, Maja, Kabesch, Michael, Kermode, Allan G., Kilpatrick, Trevor J., Kim, Cecilia, Klopp, Norman, Koivisto, Keijo, Larsson, Malin, Lathrop, Mark, Lechner-Scott, Jeannette S., Leone, Maurizio A., Leppä, Virpi, Liljedahl, Ulrika, Lima Bomfim, Izaura, Lincoln, Robin R., Link, Jenny, Liu, Jianjun, Lorentzen, Åslaug R., Lupoli, Sara, Macciardi, Fabio, Mack, Thomas, Marriott, Mark, Martinelli, Vittorio, Mason, Deborah, McCauley, Jacob L., Mentch, Frank, Mero, Inger-Lise, Mihalova, Tania, Montalban, Xavier, Mottershead, John, Myhr, Kjell-Morten, Naldi, Paola, Ollier, William, Page, Alison, Palotie, Aarno, Pelletier, Jean, Piccio, Laura, Pickersgill, Trevor, Piehl, Fredrik, Pobywajlo, Susan, Quach, Hong L., Ramsay, Patricia P., Reunanen, Mauri, Reynolds, Richard, Rioux, John D., Rodegher, Mariaemma, Roesner, Sabine, Rubio, Justin P., Rückert, Ina-Maria, Salvetti, Marco, Salvi, Erika, Santaniello, Adam, Schaefer, Catherine A., Schreiber, Stefan, Schulze, Christian, Scott, Rodney J., Sellebjerg, Finn, Selmaj, Krzysztof W., Sexton, David, Shen, Ling, Simms-Acuna, Brigid, Skidmore, Sheila, Sleiman, Patrick M. A., Smestad, Cathrine, Sørensen, Per Soelberg, Søndergaard, Helle Bach, Stankovich, Jim, Strange, Richard C., Sulonen, Anna-Maija, Sundqvist, Emilie, Syvänen, Ann-Christine, Taddeo, Francesca, Taylor, Bruce, Blackwell, Jenefer M., Tienari, Pentti, Bramon, Elvira, Tourbah, Ayman, Brown, Matthew A., Tronczynska, Ewa, Casas, Juan P., Tubridy, Niall, Corvin, Aiden, Vickery, Jane, Jankowski, Janusz, Villoslada, Pablo, Markus, Hugh S., Wang, Kai, Mathew, Christopher G., Wason, James, Palmer, Colin N. A., Wichmann, H-Erich, Plomin, Robert, Willoughby, Ernest, Rautanen, Anna, Winkelmann, Juliane, Wittig, Michael, Trembath, Richard C., Yaouanq, Jacqueline, Viswanathan, Ananth C., Zhang, Haitao, Wood, Nicholas W., Zuvich, Rebecca, Deloukas, Panos, Langford, Cordelia, Duncanson, Audrey, Oksenberg, Jorge R., Pericak-Vance, Margaret A., Haines, Jonathan L., Olsson, Tomas, Hillert, Jan, Ivinson, Adrian J., De Jager, Philip L., Peltonen, Leena, Stewart, Graeme J., Hafler, David A., Hauser, Stephen L., McVean, Gil, Donnelly, Peter, and Compston, Alastair

Published
2011
Full Text
View/download PDF

27. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders

Author

Louapre, Céline, primary, Maillart, Elisabeth, additional, Papeix, Caroline, additional, Zeidan, Sinead, additional, Biotti, Damien, additional, Lepine, Zoé, additional, Wahab, Abir, additional, Zedet, Mickael, additional, Labauge, Pierre, additional, Tilikete, Caroline, additional, Pique, Julie, additional, Tourbah, Ayman, additional, Mathey, Guillaume, additional, Dimitri Boulos, Dalia, additional, Branger, Pierre, additional, Kremer, Laurent Daniel, additional, Marignier, Romain, additional, Collongues, Nicolas, additional, and De Seze, Jérôme, additional

Published
2020
Full Text
View/download PDF

29. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients

Author

Whittam, Daniel H, primary, Cobo-Calvo, Alvaro, additional, Lopez-Chiriboga, A Sebastian, additional, Pardo, Santiago, additional, Gornall, Matthew, additional, Cicconi, Silvia, additional, Brandt, Alexander, additional, Berek, Klaus, additional, Berger, Thomas, additional, Jelcic, Ilijas, additional, Gombolay, Grace, additional, Oliveira, Luana Micheli, additional, Callegaro, Dagoberto, additional, Kaneko, Kimihiko, additional, Misu, Tatsuro, additional, Capobianco, Marco, additional, Gibbons, Emily, additional, Karthikeayan, Venkatraman, additional, Brochet, Bruno, additional, Audoin, Bertrand, additional, Mathey, Guillaume, additional, Laplaud, David, additional, Thouvenot, Eric, additional, Cohen, Mikaël, additional, Tourbah, Ayman, additional, Maillart, Elisabeth, additional, Ciron, Jonathan, additional, Deschamps, Romain, additional, Biotti, Damien, additional, Rostasy, Kevin, additional, Neuteboom, Rinze, additional, Hemingway, Cheryl, additional, Forsyth, Rob, additional, Matiello, Marcelo, additional, Webb, Stewart, additional, Hunt, David, additional, Murray, Katy, additional, Hacohen, Yael, additional, Lim, Ming, additional, Leite, M Isabel, additional, Palace, Jacqueline, additional, Solomon, Tom, additional, Lutterotti, Andreas, additional, Fujihara, Kazuo, additional, Nakashima, Ichiro, additional, Bennett, Jeffrey L, additional, Pandit, Lekha, additional, Chitnis, Tanuja, additional, Weinshenker, Brian G, additional, Wildemann, Brigitte, additional, Sato, Douglas Kazutoshi, additional, Kim, Su-Hyun, additional, Huda, Saif, additional, Kim, Ho Jin, additional, Reindl, Markus, additional, Levy, Michael, additional, Jarius, Sven, additional, Tenembaum, Silvia, additional, Paul, Friedemann, additional, Pittock, Sean, additional, Marignier, Romain, additional, and Jacob, Anu, additional

Published
2020
Full Text
View/download PDF

31. MSJ849511_supplemental_figure – Supplemental material for Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study

Author

Ciron, Jonathan, Cobo-Calvo, Alvaro, Audoin, Bertrand, Bourre, Bertrand, Brassat, David, Cohen, Mikael, Collongues, Nicolas, Deschamps, Romain, Durand-Dubief, Françoise, Laplaud, David, Maillart, Elisabeth, Papeix, Caroline, Zephir, Hélène, Bereau, Matthieu, Brochet, Bruno, Carra-Dallière, Clarisse, Derache, Nathalie, Gagou-Scherer, Clarisse, Henry, Carole, Kerschen, Philippe, Mathey, Guillaume, Maubeuge, Nicolas, Maurousset, Aude, Montcuquet, Alexis, Moreau, Thibault, Prat, Christophe, Taithe, Frédéric, Thouvenot, Eric, Tourbah, Ayman, Rollot, Fabien, Vukusic, Sandra, and Marignier, Romain

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, MSJ849511_supplemental_figure for Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study by Jonathan Ciron, Alvaro Cobo-Calvo, Bertrand Audoin, Bertrand Bourre, David Brassat, Mikael Cohen, Nicolas Collongues, Romain Deschamps, Françoise Durand-Dubief, David Laplaud, Elisabeth Maillart, Caroline Papeix, Hélène Zephir, Matthieu Bereau, Bruno Brochet, Clarisse Carra-Dallière, Nathalie Derache, Clarisse Gagou-Scherer, Carole Henry, Philippe Kerschen, Guillaume Mathey, Nicolas Maubeuge, Aude Maurousset, Alexis Montcuquet, Thibault Moreau, Christophe Prat, Frédéric Taithe, Eric Thouvenot, Ayman Tourbah, Fabien Rollot, Sandra Vukusic and and Romain Marignier in Multiple Sclerosis Journal

Published
2019
Full Text
View/download PDF

33. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders.

Author

Louapre, Céline, Maillart, Elisabeth, Papeix, Caroline, Zeidan, Sinead, Biotti, Damien, Lepine, Zoé, Wahab, Abir, Zedet, Mickael, Labauge, Pierre, Tilikete, Caroline, Pique, Julie, Tourbah, Ayman, Mathey, Guillaume, Dimitri Boulos, Dalia, Branger, Pierre, Kremer, Laurent Daniel, Marignier, Romain, Collongues, Nicolas, and De Seze, Jérôme

Subjects
COVID-19, NEUROMYELITIS optica, MYELIN oligodendrocyte glycoprotein, SARS-CoV-2, DISABILITIES, IMMUNOSUPPRESSIVE agents
Abstract

Background: Outcomes of coronavirus disease 2019 (COVID‐19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown. Methods: We conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID‐19 between 1 March 2020 and 30 June 2020. Main outcome was COVID‐19 severity score assessed on a seven‐point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death). Results: Fifteen cases (mean [SD] age: 39.3 [14.3] years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24‐year‐old patient with positive aquaporine‐4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti‐CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean [SD] age: 37.0 [13.4] years), with a longer disease duration (mean [SD]: 8.3 [6.3] years) and had a lower expanded disability severity score (EDSS) score (median [range] EDSS: 2.5 [0–4]) relative to patients requiring hospitalization (mean [SD] age: 44.0 [16.4] years, mean [SD] disease duration: 5.8 [5.5] years, median [range] EDSS: 4 [0–6.5]). Conclusions: COVID‐19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID‐19; however, we recommend personal protective measures to reduce risk of SARS‐CoV‐2 infection in this immunocompromised population. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

35. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults

Author

Cobo-Calvo, Alvaro, Ruiz, Anne, Maillart, Elisabeth, Audoin, Bertrand, Zephir, Helene, Bourre, Bertrand, Ciron, Jonathan, Collongues, Nicolas, Brassat, David, Cotton, Francois, Papeix, Caroline, Durand-Dubief, Francoise, Laplaud, David, Deschamps, Romain, Cohen, Mikaël, Biotti, Damien, Ayrignac, Xavier, Tilikete, Caroline, Thouvenot, Eric, Brochet, Bruno, Dulau, Cecile, Moreau, Thibault, Tourbah, Ayman, Lebranchu, Pierre, Michel, Laure, Lebrun-Frenay, Christine, Montcuquet, Alexis, Mathey, Guillaume, Debouverie, Marc, Pelletier, Jean, Labauge, Pierre, Derache, Nathalie, Coustans, Marc, Rollot, Fabien, De Seze, Jerome, Vukusic, Sandra, Marignier, Romain, Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques (BMNST), and Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
Published
2018

36. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study

Author

Ciron, Jonathan, primary, Cobo-Calvo, Alvaro, additional, Audoin, Bertrand, additional, Bourre, Bertrand, additional, Brassat, David, additional, Cohen, Mikael, additional, Collongues, Nicolas, additional, Deschamps, Romain, additional, Durand-Dubief, Françoise, additional, Laplaud, David, additional, Maillart, Elisabeth, additional, Papeix, Caroline, additional, Zephir, Hélène, additional, Bereau, Matthieu, additional, Brochet, Bruno, additional, Carra-Dallière, Clarisse, additional, Derache, Nathalie, additional, Gagou-Scherer, Clarisse, additional, Henry, Carole, additional, Kerschen, Philippe, additional, Mathey, Guillaume, additional, Maubeuge, Nicolas, additional, Maurousset, Aude, additional, Montcuquet, Alexis, additional, Moreau, Thibault, additional, Prat, Christophe, additional, Taithe, Frédéric, additional, Thouvenot, Eric, additional, Tourbah, Ayman, additional, Rollot, Fabien, additional, Vukusic, Sandra, additional, and Marignier, Romain, additional

Published
2019
Full Text
View/download PDF

37. Clinical Evaluation of a Software Medical Device for the Self-Assessment of Patients Living with Multiple Sclerosis: Results of the MSCopilot Study (P3.2-012)

Author

Maillart, Elisabeth, primary, Labauge, Pierre, additional, Cohen, Mikael, additional, Maarouf, Adil, additional, Vukusic, Sandra, additional, Donzé, Cécile, additional, Gallien, Philippe, additional, De Sèze, Jérôme, additional, Bourre, Bertrand, additional, Moreau, Thibault, additional, Bieuvelet, Séverine, additional, Vallée, Morgane, additional, Bertillot, Fabien, additional, Argoud, Anne-Laure, additional, Zinai, Saad, additional, and Tourbah, Ayman, additional

Published
2019
Full Text
View/download PDF

46. Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Author

Rouzaud, Claire, Hautecoeur, Patrick, Donze, Cécile, Heinzlef, Olivier, Dinh, Aurélien, Creange, Alain, Abdullatif, Alkhedr, Audouin, Bertrand, Tourbah, Ayman, Berger, Eric, Bourre, Bertrand, Brochet, Bruno, Mekies, Claude, Cabre, Philippe, Papeix, Caroline, Casez, Olivier, Brassat, David, Defer, Gilles, Derache, Nathalie, De Seze, Jérôme, Dive, Dominique, LePage, Emmanuelle, Fromont, Agnes, Gouider, Riadh, Edan, Gilles, Pelletier, Jean, Grimaud, Jérôme, Guennoc, Anne-Marie, Camdessanché, Jean-Philippe, Kwiatkowski, Arnaud, Laplaud, David, Lebrun, Christine, Debouverie, Marc, Coustans, Marc, Gout, Olivier, La Rochelle, Olivier Anne, Ouallet, Jean-Christophe, Cavelou, Pierre, Labauge, Pierre, Vermersch, Patrick, Wiertlewski, Sandrine, Vukusic, Sandra, Marignier, Romain, Schluep, Myriam, Seeldrayers, Pierrette, Slassi, Ilham, Stankoff, Bruno, Thaite, Frederic, Moreau, Thibault, Thouvenot, Eric, Zephir, Hélène, Ciron, Jonhatan, Collongues, Nicolas, Kerschen, Philippe, Cohen, Mikael, Gueguen, Antoine, Mathey, Guillaume, Carra, Clarisse, Bernady, Patricia, Faucheux, Jean Marc, Planque, Evelyne, Donze, Cecile, Ruet, Aurélie, Mouzawakh, Catherine, and Pittion, Sophie

Published
2017
Full Text
View/download PDF

47. Ultra-small Super Paramagnetic Iron Oxide predicts higher disease activity in clinically isolated syndrome

Author

Maarouf, Adil, Ferré, Jean, Zaaraoui, W, Le Troter, Arnaud, Bannier, Elise, Berry, Isabelle, Guye, Maxime, Pierot, Laurent, Barillot, Christian, Pelletier, Jean, Tourbah, Ayman, Edan, Gilles, Audoin, Bertrand, Ranjeva, Jean-Philippe, Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes], CHU Pontchaillou [Rennes], Vision, Action et Gestion d'informations en Santé (VisAGeS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Inria Rennes – Bretagne Atlantique, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE (IRISA-D5), Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Service de Médecine Nucléaire - Pierre-Paul Riquet [CHU Toulouse], Pôle imagerie médicale [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] (CEMEREM), Hôpital de la Timone [CHU - APHM] (TIMONE)-Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Université de Reims Champagne-Ardenne (URCA), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Hôpital de la Timone [CHU - APHM] (TIMONE), Service de Neurologie [Rennes] = Neurology [Rennes], Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - AP-HM] (CEMEREM), CentraleSupélec-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Rennes (ENS Rennes)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Télécom Bretagne-Université de Rennes 1 (UR1), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École normale supérieure - Rennes (ENS Rennes)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service de Médecine Nucléaire [Toulouse], CHU Toulouse [Toulouse], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)- Hôpital de la Timone [CHU - APHM] (TIMONE), Université de Bretagne Sud (UBS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Rennes (ENS Rennes)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-CentraleSupélec-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE (IRISA-D5), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Bretagne Sud (UBS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Inria Rennes – Bretagne Atlantique, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, and Barillot, Christian

Subjects
Multiple sclerosis, clinically isolated syndrome, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], macrophage, USPIO, MRI
Abstract

Background: Macrophages are important components of inflammatory processes inmultiple sclerosis, closely linked to axonal loss, and can now be observed in-vivo usingUltra-Small super-Paramagnetic Iron Oxide (USPIO). We aimed to determine theprevalence of macrophage infiltration and to assess the predictive value on diseaseactivity and tissue injury after one year in clinical isolated syndrome patients.Methods: Thirty-five patients were imaged using conventional-MRI, magnetizationtransfer ratio (MTR) to assess tissue destructuration, gadolinium (Gd) to probe bloodbrain barrier integrity, and USPIO to study macrophage infiltration.Results: At baseline, patients showed 17 USPIO-positive lesions reflecting infiltrationof macrophages present from the onset. This infiltration was associated with higherlocal tissue destructuration as emphasized by lower MTR values of USPIO-positive/Gdpositivelesions compared to USPIO-negative/Gd-positive and to non-enhanced lesions,at baseline and Month-12, and no difference between USPIO-negative/Gd-positive andnon-enhanced lesions. While at baseline T2-lesion load of patients with USPIOenhancementcompared to patients with Gd-enhancement was not different, it washigher at Month-12. T1-lesion load was also higher at Month-12 in patients withUSPIO-enhancement.Conclusion: Infiltration of activated macrophages evidenced by USPIO enhancement,is present at the onset of MS and is associated with higher local and global progressionof tissue destructuration.

Published
2017

48. MMP9 is decreased in natalizumab-treated MS patients at risk for PML

Author

Fissolo, Nicolas, Pignolet, Béatrice, Matute-Blanch, Clara, Triviño, Juan Carlos, Miró, Berta, Mota, Miriam, Perez-Hoyos, Santiago, Sanchez, Alex, Vermersch, Patrick, Ruet, Aurélie, Sèze, Jérome, Labauge, Pierre, Vukusic, Sandra, Papeix, Caroline, Almoyna, Laurent, Tourbah, Ayman, Clavelou, Pierre, Moreau, Thibault, Pelletier, Jean, Lebrun-Frenay, Christine, Montalban, Xavier, Brassat, David, Comabella, Manuel, BIONAT, BEST-MS, network, SFSEP, Departamento de Fisica Aplicada [Bilbao], Universidad del Pais Vasco / Euskal Herriko Unibertsitatea [Espagne] (UPV/EHU), Statistics Department, University of Barcelona, Institut de Recerca, Vall d'Hebron University Hospital [Barcelona], Inflammation: mécanismes et régulation et interactions avec la nutrition et les candidoses, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, Laboratoire d'Immunologie (EA 2686), Université de Lille, Droit et Santé, Service de neurologie D, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Bordeaux (UB), Service de neurologie [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Physiopathologie du système nerveux central - Institut François Magendie, Université Bordeaux Segalen - Bordeaux 2-IFR8-Institut National de la Santé et de la Recherche Médicale (INSERM), Neurocentre Magendie-U862, Institut François Magendie, and Université de Bordeaux, Institut National de la Santé et de la Recherche Médicale (INSERM), CIC de Strasbourg, Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [Hospices civils de Lyon - Hôpital Pierre Wertheimer], Hospices Civils de Lyon (HCL)-Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC), Service de neurologie [Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Centre de compétence de la Sclérose Latérale Amyotrophique [CHU Clermont-Ferrand] (SLA), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Universitaire de Nice (CHU Nice), Medical Image Analysis Center (MIAC AG), Neurologie vasculaire, pathologie neuro-dégénérative et explorations fonctionnelles du système nerveux [Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, parasitic diseases, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, snc
Abstract

International audience; OBJECTIVE: To identify biomarkers associated with the development of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with natalizumab (NTZ). METHODS: Relapsing-remitting MS (RRMS) patients who developed PML under NTZ therapy (pre-PML) and non-PML natalizumab-treated patients (NTZ-ctr) were included in the study. Cryopreserved peripheral blood mononuclear cells (PBMC) and serum samples collected at baseline, at one- and two-year treated time points, and during PML were analyzed for gene expression by RNA-sequencing and for serum protein levels by LUMINEX and ELISA assays respectively. RESULTS: Among top differentially expressed genes in the RNA-sequencing between pre-PML and NTZ-ctr patients, pathway analysis revealed a high representation of genes belonging to the following categories: pro-angiogenic factors (MMP9, VEGFA), chemokines (CXCL1, CXCL5, IL8, CCL2), cytokines (IL1B, IFNG), and plasminogen- and coagulation-related molecules (SERPINB2, PLAU, PLAUR, TFPI, THBD). Serum protein levels for these candidates were measured in a two-step manner in a screening cohort and a validation cohort of pre-PML and NTZ-ctr patients. Only MMP9 was validated and, in pre-PML patients MMP9 protein levels were significantly reduced at baseline compared with NTZ-ctr patients and levels remained lower at later time points during NTZ treatment. INTERPRETATION: The results from this study suggest that the pro-angiogenic factor MMP9 may play a role as biomarker associated with the development of PML in MS patients treated with NTZ. This article is protected by copyright. All rights reserved.

Published
2017

49. Natalizumab-PML survivors with subsequent MS treatment

Author

Maillart, Elisabeth, Vidal, Jean-Sebastien, Brassat, David, Stankoff, Bruno, Fromont, Agnès, de Sèze, Jérôme, Taithe, Frédéric, Clavelou, Pierre, Bourre, Bertrand, Delvaux, Valérie, Rico, Audrey, Labauge, Pierre, Tourbah, Ayman, Lebrun, Christine, Pelletier, Jean, Moreau, Thibault, Louapre, Céline, Lubetzki, Catherine, Papeix, Caroline, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Department of Gerontology, Broca Hospital, APHP, Paris, Département Neurologie [CHU Toulouse], Pôle Neurosciences [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Saint-Antoine [AP-HP], Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Department of Neurology, University Hospital of Clermont-Ferrand, Department of neurology, university hospital of Rouen, Department of Neurology, University Hospital of Liège, Belgium, Pôle de Neurosciences Cliniques, Service de Neurologie, APHM, Hôpital de la Timone, Aix-Marseille University, Marseille, France, Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] (CEMEREM), Hôpital de la Timone [CHU - APHM] (TIMONE)-Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Department of Neurology, University Hospital of Montpellier, Department of Neurology (A.T.), University Hospital of Reims, and Department of Neurology, University Hospital of Nice

Subjects
viruses, virus diseases, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy
Abstract

International audience; Objective: To describe the clinico-radiologic outcome of MS patients with natalizumab-related progressive multifocal leukoencephalopathy (Nz-PML) surviving and receiving disease-modifying therapy (DMT). Methods: We describe clinical and radiologic evolution of Nz-PML survivors in an observational retrospective multicenter cohort to clarify the effect of different subsequent MS DMT strategies. Twenty-three patients from 11 centers were analyzed. Outcomes were (1) clinical efficacy of post-PML MS DMT, (2) radiologic efficacy of post-PML MS DMT, (3) radiologic evolution of PML lesion, and (4) disability progression. Results: There was no clinical worsening of PML symptoms with a stability of Expanded Disability Status Scale at the last follow-up. No relapse was reported with fingolimod and dimethyl fumarate. No radiologic worsening of Nz-PML lesion was observed at the end of the follow-up. Conclusion: In this large cohort of patients with Nz-PML, MS therapies given after Nz discontinuation were not associated with PML worsening. A larger cohort with longer follow-up will be necessary to confirm this therapeutic strategy.

Published
2017

50. Soutien social et fatigue dans la sclérose en plaques: Édition d’actes de colloque

Author

Montreuil, Michèle, Henry, A., Tourbah, Ayman, Deschamps, R., Laboratoire de Psychopathologie et Neuropsychologie (LPN), Université Paris 8 Vincennes-Saint-Denis (UP8), and Shtalbi, Haki

Subjects
[SCCO]Cognitive science, [SCCO.NEUR]Cognitive science/Neuroscience, [SCCO.PSYC]Cognitive science/Psychology, [SCCO.NEUR] Cognitive science/Neuroscience, [SCCO.PSYC] Cognitive science/Psychology, [SCCO] Cognitive science, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results